TEM News
Archived Headlines
- US IPO Week Ahead: Summer IPO market continues with precision medicine and radiopharmaceuticals 06/07/24
- Precision medicine company Tempus AI sets terms for $400 million IPO 06/05/24
- Renaissance Capital's May IPO Market Update 06/03/24
- US IPO Weekly Recap: Specialty insurer Bowhead sole IPO to debut as more names join the pipeline 05/24/24
- Health-tech startup Tempus AI files for an estimated $600 million IPO 05/20/24
As VC funding for AI startups jumps, interested investors should watch the IPO market
Artificial intelligence (AI) is booming, and investors are seeking ways to capitalize on that growth. In addition to the billions poured into publicly-traded stocks like Nvidia, Microsoft, Meta, and Arm, venture funding for AI startups reached a new quarterly...read more
Updated: Renaissance Capital's 2Q 2024 US IPO Market Review
US IPO Market Slowly Climbs to a Two-Year High IPO activity hit a two-year high in the second quarter of 2024 but still came in below expectations, with 39 IPOs raising a combined $8.9 billion as...read more
US IPO Weekly Recap: Precision medicine IPO Tempus AI posts a modest gain in its debut
Just one large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading. Precision medicine company Tempus AI (TEM) priced at the high end to raise $411 million at a $6.4 billion market cap....read more
Genomics testing and data firm Tempus AI prices IPO at $37, the high end of the range
Tempus AI, which provides data and analytics tools for precision medicine, raised $411 million by offering 11.1 million shares at $37, the high end of the range of $35 to $37. At pricing, the company commands a fully diluted market value of more than $6 billion....read more